Abstract. microRNAs (miRNAs) play critical roles in hepatocellular carcinoma (HCC). However, the expression and biological function of miR-3653 in HCC remain unknown. The present study demonstrated that miR-3653 expression was significantly decreased in HCC tissues and cells using qRT-PCR. A decreased miR-3653 level was associated with unfavorable clinical features and poor prognosis of HCC patients. MTT, BrdU, Transwell and western blot assays showed that miR-3653 overexpression inhibited the growth, migration, invasion and epithelial-mesenchymal transition (EMT) of HCCLM3 cells while its knockdown promoted the growth and metastatic ability of Hep3B cells. In vivo experiments showed that miR-3653 overexpression inhibited the subcutaneous and the lung metastasis of HCCLM3 cells in nude mice. Mechanistically, integrin-β1 (ITGB1) was identified to be the downstream target of miR-3653 in HCC. ITGB1 overexpression reversed the inhibitory effects of miR-3653 on the growth, metastasis and EMT of HCCLM3 cells.
Introduction
MicroRNAs (miRNAs) are a cluster of short non-coding RNAs (~20 nucleotides long) (1) . miRNAs can post-transcriptionally regulate gene expression by interacting with the 3' untranslated region (3'-UTR) of targeted messenger RNAs (mRNAs). Functionally, miRNAs were found to play critical roles in various human diseases including human cancers. Numerous miRNAs have been found to be aberrantly expressed in human cancers and have been proposed as promising biomarkers and prognostic predictors for cancer patients (2) . Among these cancer-associated miRNAs, miR-3653 is a novel cancer-associated miRNA. miRNA expression profiles showed that miR-3653 is aberrantly expressed in lung adenocarcinoma (3) and colon cancer (4) . A decreased expression level of miR-3653 was found to be correlated with a poor prognosis of lung adenocarcinoma patients.
Hepatocellular carcinoma (HCC) is a fatal malignancy affecting millions of individuals worldwide. HCC ranks as the second leading cause of cancer-related death (5) . The overall survival for HCC patients is unsatisfactory, and the 5-year survival rate of HCC patients is less than 40%; and even worse for those in advanced stages (6) . Uncontrolled growth and occurrence of local and systemic metastasis are the main reasons for the poor prognosis of HCC patients. During the last two decades, increasing studies have shown that miRNAs play critical roles in the progression of HCC. miRNAs were found to regulate the growth, metastasis and drug resistance of HCC cells. However, the expression and biological functions of miR-3653 in HCC remain unknown.
The present study demonstrated that compared with adjacent non-tumor tissues, miR-3653 expression was significantly decreased in HCC tissues. Patients with a low miR-3653 level showed decreased overall and disease-free survival. Decreased expression of miR-3653 was found to be associated with unfavorable clinicopathological features (large tumor size and occurrence of metastasis) of HCC patients. Using gain-and loss-of-function assays, miR-3653 was found to inhibit the growth and metastasis of HCC cells. In vivo assays showed that miR-3653 slowed down the subcutaneous growth and reduced the lung metastasis of HCC cells in nude mice. Mechanistically, the present study revealed that integrin-β1 (ITGB1) was the downstream target of miR-3653 in HCC cells. Moreover, we demonstrated that targeting ITGB1 was critical for the biological functions of miR-3653 in HCC.
Materials and methods
Clinical tissues. HCC tissues along with adjacent non-tumor tissues were collected from 60 HCC patients (37 male and  23 female GAT GAC TCC TGT GTT CC-3'; N-cadherin forward, 5'-GTC ATC TTG ATC TCA TAA CGC TGG-3' and reverse, 5'-AGC CCA TCT GTA CCT GTG GTT CA-3'; ITGB1 forward, 5'-TCA GAA TTG GAT TTG GCT CAT TT-3' and reverse, 5'-CCT GAG CTT AGC TGG TGT TGT G-3'; GAPDH forward, 5'-GGT CAC CAG GGC TGC TTT TA-3' and reverse, 5'-GGA TCT CGC TCC TGG AAG ATG-3'. The relative expression levels of miRNAs or mRNAs were determined using ΔΔCq-based fold-change calculations as previously described (7, 8) .
Western blot analysis. Proteins in clinical tissues and HCC cells were extracted using RIPA buffer and subjected to concentration measurements using BCA kit. After being separated in SDS-PAGE gels, the protein (20 µg) on SDS-PAGE gels (4-20%) were transferred to polyvinylidene fluoride membrane. These membranes were incubated with 5% non-fat dry milk (diluted in TBST) at room temperature for 1 h and primary antibodies of E-cadherin ( ) resuspended in 200 µl basal DMEM were added to the upper chamber of a Transwell insert. A total of 600 µl serum-containing DMEM (20% FBS) used as chemoattractant was added to the lower chamber. For the invasion experiments, 100 µl Matrigel (diluted in DMEM at the ratio of 1:8) was added to the bottom of the upper chamber. Twenty-four hours later, cells that had migrated through the membrane were stained with crystal violet. The number of migrated or invaded cells was counted under a light microscope at x40 magnification.
Luciferase assay. 3'-UTR of ITGB1 containing the binding sequences for miR-3653 or the mutated 3'-UTR of ITGB1 was used to construct the wild-type ITGB1-3'-UTR or mutant ITGB1-3'-UTR. HCC cells in 12-well plates were transfected with wild-type or mutant 3'-UTR of ITGB1 along with miR-3653 mimic or inhibitor or the corresponding control vector. After co-transfection, the luciferase activity was measured by luciferase reporter kit (Promega Corporation, Madison, WI, USA).
In vivo tumor growth and metastasis assay. For the in vivo tumor growth studies, nude mice (6-weeks of age, 4 female mice each group) were injected with HCCLM3 cells overexpressing miR-3653 or cells in the control group (1x10 6 ). The length and width of tumor nodules were measured every 7 days. After 28 days, the nude mice were sacrificed using cervical dislocation and the subcutaneous tumors were removed and subjected to measurement of the volume (volume = width 2 x length/2). For tail vein injection model, HCCLM3 cells overexpressing miR-3653 or cells in the control group (5x10 4 ) were injected into nude mice (4 mice each group) through the tail vein. All mice (Saierbio, Tianjing, China), with 4 female mice in each group, were maintained in specific pathogen-free (SPF) rooms under a 12-h light/dark cycle, with two mice in each static filter-topped cage. The initial weight of these mice were approximately 20 g. Eight weeks after tail vein injection, these nude mice were sacrificed using cervical dislocation and the lungs were removed and subjected to H&E staining. The protocols regarding the in vivo manipulations were approved by the Animal Care Committee of the First Affiliated Hospital of Xinjiang Medical University.
Statistical analysis. All quantitative data are presented as the mean ± standard error of the mean (SEM) from at least three independent replicates. SPSS software 13.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis, a two-tailed Student t-test and Kaplan-Meier analysis were used to analyze the differences between two groups. One-way analysis of variance (ANOVA) was used to examine the statistical difference between multiple groups with least significant difference (LSD) test as post hoc test. Differences between groups were considered statistically significant at P<0.05.
Results

miR-3653 expression is decreased in HCC tissues and cells.
qRT-PCR of the clinical specimens showed that compared with non-tumor tissues, HCC tissues showed a significantly decreased level of miR-3653 (P<0.05; Fig. 1A ). Subgroup analysis showed that compared with tumors >5 cm, small tumors tumors ≤5 cm showed significantly increased level of miR-3653 (P<0.05; Fig. 1B) . Moreover, patients with local or systemic metastasis showed a significantly decreased level of miR-3653 than those without metastasis (P<0.05; Fig. 1C ). Finally, we compared the expression level of miR-345 in HCC cell lines and L-02 cells. Compared with that in L-02 cells, the level of miR-3653 in the four HCC cell lines was significantly decreased (P<0.01; Fig. 1D ). Among the four HCC cell lines, the expression level of miR-3653 was highest in the Hep3B cells and lowest in the HCCLM3 cells. Furthermore, we investigated the association between the miR-3653 level and patient prognosis. Kaplan-Meier survival analysis showed that patients with a low miR-3653 level had significantly decreased overall survival (P<0.05; Fig. 2A ) and disease-free survival (P<0.05; Fig. 2B ).
miR-3653 inhibits the growth and metastatic ability of HCC cells in vitro.
To determine the biological functions of miR-3653 in HCC cells, we performed gain-and loss-of function experiments in HCCLM3 and Hep3B cells, respectively. Transfection of miR-3653 mimics into HCCLM3 cells effectively increased the miR-3653 level (P<0.05; Fig. 3A ). MTT and BrdU assays showed that overexpression of miR-3653 led to decreased cell viability and proliferation of HCCLM3 cells (P<0.05; Fig. 3B and C) . Transwell assay showed that forced expression of miR-3653 led to significantly decreased ability of cell migration and invasion (P<0.05; Fig. 3D ). In contrast, we performed miR-3653 knockdown in Hep3B cells. miR-3653 inhibitor significantly decreased the miR-3653 level in Hep3B cells (P<0.05; Fig. 4A) , and led to increased cell viability, proliferation, migration and invasion (P<0.05; Fig. 4B-D) . 
miR-345 inhibits the EMT of HCC cells.
EMT has been widely accepted as a critical mechanism for cancer metastasis (9) . Therefore, we evaluated the EMT status after altering the miR-3653 level in HCCLM3 and Hep3B cells. qRT-PCR showed that overexpression of miR-3653 increased E-cadherin mRNA and decreased N-cadherin mRNA (P<0.05; Fig. 5A ). Western blot analysis showed that forced expression of miR-3653 led to elevated E-cadherin protein and decreased N-cadherin protein (P<0.05; Fig. 5B ). In contrary, miR-3653 knockdown decreased the mRNA and protein level of E-cadherin (P<0.05; Fig. 5C and D) and increased N-cadherin expression (P<0.05; Fig. 5C and D) . 
ITGB1 is the downstream target of miR-3653 in HCC.
We further searched the public database TargetScan (http://www.targetscan.org) to identify potential downstream targets of miR-3653. ITGB1, a well-known oncogenic protein which plays a critical role in HCC progression (10) , was one of the predicted downstream targets of miR-3653. As shown in Fig. 7A, ITGB1 3 '-UTR contained the binding sequences for miR-3653. Luciferase assay showed that overexpression of miR-3653 decreased the luciferase activity of wild-type ITGB1 3'-UTR while miR-3653 knockdown increased that of ITGB1 3'-UTR (P<0.05; Fig. 7B ). Neither miR-3653 overexpression nor miR-3653 knockdown affected the luciferase of mutated ITGB1 3'-UTR (Fig. 7B) . qRT-PCR and western blot analysis showed that miR-3653 overexpression decreased the mRNA and protein level of ITGB1 in HCCLM3 cells (P<0.05; Fig. 7C and D) . Knockdown of miR-3653 increased the expression of ITGB1 in Hep3B cells (P<0.05; Fig. 7E and F) . To further confirm the regulatory effect of miR-3653 on ITGB1, we detected the ITGB1 expression in HCC tissues. Compared with those with high miR-3653 level, tissues with low miR-3653 level showed increased expression of ITGB1. The IHC score of ITGB1 in HCC tissues with low miR-3653 level was significantly higher than that in tissues with high miR-3653 level (P<0.05; Fig. 7G ). 
ITGB1 mediates the biological functions of miR-3653 in HCC.
Since ITGB1 was confirmed as the downstream target of miR-3653 in HCC, we further explored whether ITGB1 mediates the biological functions of miR-3653 in HCC. qRT-PCR showed that transfection of the ITGB1 vector significantly increased the ITGB1 mRNA in Hep3B cells (P<0.05; Fig. 8A ). Western blot analysis showed that transfection of ITGB1 vector in HCCLM3 cells overexpressing miR-3653 significantly increased ITGB1 expression and reversed the increase of E-cadherin and the decrease of N-cadherin caused by miR-3653 overexpression (P<0.05; Fig. 8B ). Functionally, forced expression of ITGB1 abrogated the decrease of cell viability and proliferation caused by miR-3653 overexpression (P<0.05; Fig. 8C and D) . Transwell assay showed that ITGB1 overexpression reversed the decrease of cell migration and invasion induced by miR-3653 overexpression (P<0.05; Fig. 8E ).
Discussion
Hepatocellular carcinoma (HCC) is a fetal disease affecting millions of individuals worldwide. For patients in advanced stages, few effective options are available. The critical molecular mechanisms responsible for HCC progression remain unknown. Previous studies have confirmed that microRNAs (miRNAs) play critical roles in HCC progression (11, 12) . Numerous cancer-associated miRNAs have been found to affect the growth, metastasis, stem cell formation and drug resistance of HCC cells (13) (14) (15) (16) . miR-3653 is a novel cancer-associated miRNA and has been found to be aberrantly expressed in different types of human cancers (3, 4) . However, the expression of miR-3653 in HCC remains unknown. The present study revealed for the first time that miR-3653 expression is significantly decreased in HCC tissues and cells. Patients with large tumor size or occurrence of metastasis showed a significantly decreased miR-3653 level. Survival analysis demonstrated that a decreased miR-3653 level is correlated with a poor prognosis of HCC patients. These data indicate that miR-3653 acts as a tumor suppressor in HCC.
Uncontrolled growth and local or systemic metastasis are the main reasons for the poor survival of HCC patients. In this study, using gain-and loss-of function experiments, we confirmed that miR-3653 overexpression inhibited the cell viability, proliferation, migration and invasion of HCCLM3 cells while miR-3653 knockdown led to opposite functional consequences. Previous studies demonstrated that EMT is an important mechanism of cancer metastasis. This study found that overexpression of miR-3653 resulted in increased E-cadherin level and decreased N-cadherin expression in HCCLM3 cells while knockdown of miR-3653 led to opposite effects in Hep3B cells. Thus, miR-3653 inhibits the process of EMT of HCC cells. Moreover, this study established a subcutaneous injection model and tail vein injection model to evaluate the influence of miR-3653 on the in vivo growth and metastasis of HCC cells. In vivo assays showed that forced expression of miR-3653 inhibited the growth and metastasis of HCCLM3 cells in nude mice. Taken together, this study demonstrated that miR-3653 inhibited the growth, metastasis and EMT of HCC cells.
ITGB1 functions as an oncogene in different types of human cancers (17) (18) (19) . It was found to activate the FAK/AKT pathway in cancer cells (20) . As for HCC, ITGB1 was found to promote the growth and metastasis of HCC cells (10) . In this study, the data of luciferase assay, qRT-PCR and western blot analysis consistently showed that miR-3653 could inhibit the expression of ITGB1 in HCC cells by binding with the 3'-UTR of ITGB1. Rescue experiments confirmed that ITGB1 overexpression could abrogate the inhibitory effect of miR-3653 on EMT, cell viability, proliferation and metastasis. Thus, ITGB1 is not only a downstream target of miR-3653 but also a functional mediator of miR-3653 in HCC. It is worth noting that ITGB1 was found to be under the control of many other miRNAs including miR-29a (21) and miR-124 (19) . These miRNAs were found to be aberrantly expressed in HCC (22, 23) . Therefore, the expression of ITGB1 in HCC is probably under the control of many different miRNAs.
Collectively, the present study demonstrated that miR-3653 expression is significantly decreased in HCC tissues and cells. Decreased expression of miR-3653 is associated with poor prognosis of HCC patients. miR-3653 was found to inhibit the growth, metastasis and EMT of HCC cells. Moreover, we confirmed for the first time that ITGB1 is a downstream target of miR-3653 and mediates the biological functions of miR-3653 in HCC.
